PDE5A hydrolyzes cyclic GMP (cGMP) to 5’-GMP, and it is the target of the erectile dysfunction drug sildenafil, which acts as a competitive inhibitor for cGMP degradation (Sung et al., 2003; Zhang et al., 2004). The gene discussed is PDE5A; the disease is erectile dysfunction.